118 related articles for article (PubMed ID: 28261338)
1. Predictive factors in patients with hepatocellular carcinoma receiving sorafenib therapy using time-dependent receiver operating characteristic analysis.
Nishikawa H; Nishijima N; Enomoto H; Sakamoto A; Nasu A; Komekado H; Nishimura T; Kita R; Kimura T; Iijima H; Nishiguchi S; Osaki Y
J Cancer; 2017; 8(3):378-387. PubMed ID: 28261338
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of inflammation-immunity-nutrition score on postoperative survival and recurrence in hepatocellular carcinoma patients.
Liang Y; Zhang Z; Zhong D; Lai C; Dai Z; Zou H; Feng T; Shang J; Shi Y; Huang X
Front Oncol; 2022; 12():913731. PubMed ID: 36016629
[TBL] [Abstract][Full Text] [Related]
3. Impact of albumin-bilirubin grade on survival in patients with hepatocellular carcinoma who received sorafenib: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Michitaka K; Deguchi A; Ishikawa T; Imai M; Ochi H; Joko K; Shimada N; Tajiri K; Hirooka M; Koizumi Y; Hiasa Y; Tanaka J
J Gastroenterol Hepatol; 2019 Jun; 34(6):1066-1073. PubMed ID: 30549320
[TBL] [Abstract][Full Text] [Related]
4. Changes in serum α-fetoprotein level predicts treatment response and survival in hepatocellular carcinoma patients and literature review.
Chou WC; Lee CL; Yang TS; Huang CY; Teng W; Tseng YT; Chen JS; Lin YC; Hou MM; Chang HH; Chia-Hsun Hsieh J
J Formos Med Assoc; 2018 Feb; 117(2):153-163. PubMed ID: 28392193
[TBL] [Abstract][Full Text] [Related]
5. Treating Advanced Hepatocellular Carcinoma with Sorafenib: A 10-Year Single Center Experience.
Presa Ramos J; Tavares S; Barreira A; Pimenta JL; Carvalho S; Carrola P; Pinho I
GE Port J Gastroenterol; 2023 Jun; 30(3):213-220. PubMed ID: 37387721
[TBL] [Abstract][Full Text] [Related]
6. Early α-fetoprotein response predicts survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Lee S; Kim BK; Kim SU; Park JY; Kim do Y; Ahn SH; Han KH
J Hepatocell Carcinoma; 2015; 2():39-47. PubMed ID: 27508193
[TBL] [Abstract][Full Text] [Related]
7. Value of α-fetoprotein as an early biomarker for treatment response to sorafenib therapy in advanced hepatocellular carcinoma.
Sánchez AIP; Roces LV; García IZ; López EL; Hernandez MAC; Parejo MIB; Peña-Díaz J
Oncol Lett; 2018 Jun; 15(6):8863-8870. PubMed ID: 29805623
[TBL] [Abstract][Full Text] [Related]
8. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Bruix J; Cheng AL; Meinhardt G; Nakajima K; De Sanctis Y; Llovet J
J Hepatol; 2017 Nov; 67(5):999-1008. PubMed ID: 28687477
[TBL] [Abstract][Full Text] [Related]
9. Sorafenib for Egyptian patients with advanced hepatocellular carcinoma; single center experience.
Abdel-Rahman O; Abdelwahab M; Shaker M; Abdelwahab S; Elbassiony M; Ellithy M
J Egypt Natl Canc Inst; 2014 Mar; 26(1):9-13. PubMed ID: 24565677
[TBL] [Abstract][Full Text] [Related]
10. Lactate dehydrogenase is a prognostic indicator in patients with hepatocellular carcinoma treated by sorafenib: results from the real life practice in HBV endemic area.
Li MX; Zhao H; Bi XY; Li ZY; Yao XS; Li H; Huang Z; Han Y; Zhou JG; Zhao JJ; Zhang YF; Zhao DB; Cai JQ
Oncotarget; 2016 Dec; 7(52):86630-86647. PubMed ID: 27880930
[TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of sorafenib in hepatocellular carcinoma: the impact of the Child-Pugh score.
Hollebecque A; Cattan S; Romano O; Sergent G; Mourad A; Louvet A; Dharancy S; Boleslawski E; Truant S; Pruvot FR; Hebbar M; Ernst O; Mathurin P
Aliment Pharmacol Ther; 2011 Nov; 34(10):1193-201. PubMed ID: 21958438
[TBL] [Abstract][Full Text] [Related]
12. Role of monocyte-to-lymphocyte ratio in predicting sorafenib response in patients with advanced hepatocellular carcinoma.
Zhu Z; Xu L; Zhuang L; Ning Z; Zhang C; Yan X; Lin J; Shen Y; Wang P; Meng Z
Onco Targets Ther; 2018; 11():6731-6740. PubMed ID: 30349306
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither?
Farinati F; Marino D; De Giorgio M; Baldan A; Cantarini M; Cursaro C; Rapaccini G; Del Poggio P; Di Nolfo MA; Benvegnù L; Zoli M; Borzio F; Bernardi M; Trevisani F
Am J Gastroenterol; 2006 Mar; 101(3):524-32. PubMed ID: 16542289
[TBL] [Abstract][Full Text] [Related]
14. Impact of Baseline Characteristics on the Overall Survival of HCC Patients Treated with Sorafenib: Ten Years of Experience.
Rovesti G; Orsi G; Kalliopi A; Vivaldi C; Marisi G; Faloppi L; Foschi FG; Silvestris N; Pecora I; Aprile G; Molinaro E; Riggi L; Ulivi P; Canale M; Cucchetti A; Tamburini E; Ercolani G; Fornaro L; Andreone P; Zavattari P; Scartozzi M; Cascinu S; Casadei-Gardini A
Gastrointest Tumors; 2019 Oct; 6(3-4):92-107. PubMed ID: 31768353
[TBL] [Abstract][Full Text] [Related]
15. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
16. Post-progression survival in patients with advanced hepatocellular carcinoma resistant to sorafenib.
Ogasawara S; Chiba T; Ooka Y; Suzuki E; Kanogawa N; Saito T; Motoyama T; Tawada A; Kanai F; Yokosuka O
Invest New Drugs; 2016 Apr; 34(2):255-60. PubMed ID: 26769245
[TBL] [Abstract][Full Text] [Related]
17. [A new prognostic score system of hepatocellular carcinoma following hepatectomy].
Wang YK; Bi XY; Li ZY; Zhao H; Zhao JJ; Zhou JG; Huang Z; Zhang YF; Li MX; Chen X; Wu XL; Mao R; Hu XH; Hu HJ; Liu JM; Cai JQ
Zhonghua Zhong Liu Za Zhi; 2017 Dec; 39(12):903-909. PubMed ID: 29262506
[No Abstract] [Full Text] [Related]
18. [Comparison of therapeutics effects of transcatheter arterial chemoembolization combined with iodine-125 seed implantation and sorafenib for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis].
Luo J; Zheng JP; Shao GL; Wen S; Guo LW; Zeng H; Zhang L; Qian CY; Hao WY
Zhonghua Gan Zang Bing Za Zhi; 2018 Apr; 26(4):298-304. PubMed ID: 29996343
[No Abstract] [Full Text] [Related]
19. Impact of FIB-4 index on hepatocellular carcinoma incidence during nucleos(t)ide analogue therapy in patients with chronic hepatitis B: An analysis using time-dependent receiver operating characteristic.
Tada T; Kumada T; Toyoda H; Tsuji K; Hiraoka A; Tanaka J
J Gastroenterol Hepatol; 2017 Feb; 32(2):451-458. PubMed ID: 27288655
[TBL] [Abstract][Full Text] [Related]
20. Insulin-like growth factor 1/Child-Turcotte-Pugh composite score as a predictor of treatment outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
Mohamed YI; Lee S; Xiao L; Hassan MM; Qayyum A; Hiatia R; Pestana RC; Haque A; George B; Rashid A; Duda DG; Elghazaly H; Wolff RA; Morris JS; Yao J; Amin HM; Kaseb AO
Oncotarget; 2021 Apr; 12(8):756-766. PubMed ID: 33889299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
